TSO3 : New Sale in the United States

    Ticker: TSX - TOS
    Shares Outstanding: 37,032,102

    QUEBEC CITY, March 7 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces another sale of its 125L Ozone Sterilizer to an American hospital.
This Michigan hospital is an acute care teaching hospital which has seen
significant growth in size and revenues in the last few years. Its surgical
focus includes hand, plastic, and thoracic/cardiovascular, as well as general
and urology. The hospital is a member of H2E (Hospitals for a Healthy
Environment), and demonstrates a strong commitment to protecting and
preserving the environment.
    The hospital was the first medical facility in the state of Michigan to
be recognized for its environmental excellence when it received the Clean
Corporate Citizen Award. The hospital has established a well-regarded
environmental management system that, among other things, allows it to
identify and eliminate the use of harmful chemicals and reduce the amount of
medical waste that they generate.
    "This latest sale in the United States confirms again that our
environmentally-friendly technology is well received by the market. We believe
that this sale also demonstrates the growing potential of our sales force, and
we are now reaping the rewards from their continued efforts," said Jocelyn
Vézina, the Chief Executive Officer of TSO3. "This sale yet again underlines
the benefits of having our own sales force and we believe that doubling our
sales force by the end of the year will ensure a more rapid and effective
penetration of our market. Our recent financing, which is expected to close
shortly, is giving us the means to intensify our commercialization activities
on all fronts."
    "The customer's interest in ozone sterilization was piqued by our mutual
affiliation with H2E" said Ann Hewitt, Vice President, Sales and Marketing,
TSO3. "They had been using ethylene oxide to sterilize their heat sensitive
devices; as part of their initiative in environmental responsibility, they
decided to eliminate their dependence on ETO. After evaluating the low
temperature options available in the marketplace, they chose ozone
sterilization because of its environmental safety and because it generates no
sterilant packaging waste" she added.

    About TSO3

    TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in
1998. The Company's mission is to develop and market innovative and
comprehensive sterilization solutions. TSO3 has perfected an innovative
sterilization process using ozone as the sterilizing agent. The first product
based on this technological platform is the 125L Ozone Sterilizer, which is
intended for hospital sterilization units. The 125L - named after its
125-litre/4.3-cubic-foot capacity - was designed to sterilize heat-sensitive
surgical and diagnostic devices which are expensive and in high demand from
the surgical suite. The ozone sterilization process is a safe, efficacious,
fast and cost-effective response to evolving sterilization needs.
    The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization
by Health Canada and by the U.S. Food and Drug Administration (FDA). TSO3
completed the sale of its first sterilizer in Q4 2005.
    TSO3 currently has more than 50 employees, 23 of whom work in the sales
and marketing team.
    For more information about TSO3, visit the Company's Web site at

    The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

    The TSX has neither approved nor disapproved the information contained
    herein and accepts no responsibility for it.

For further information:

For further information: Mathieu Claise, Interim Director, Corporate
Communications and Investor Relations, (418) 651-0003, Ext. 237, ir@tso3.com;
Source: TSO3 Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890